References
- SimGCRadvanyiLThe IL-2 cytokine family in cancer immunotherapyCytokine Growth Factor Rev201425437739025200249
- FlorosTTarhiniAAAnticancer cytokines: biology and clinical effects of interferon-α, Interleukin (IL)-2, IL-15, IL-21, and IL-12Semin Oncol201542453954826320059
- TianYZajacAJIL-21 and T cell differentiation: consider the contextTrends Immunol201637855756827389961
- Al-ChamiETormoAKhodayarianFRafeiMTherapeutic utility of the newly discovered properties of interleukin-21Cytokine2016826333726748727
- TangyeSGAdvances in IL-21 biology – enhancing our understanding of human diseaseCurr Opin Immunol201534310711525801685
- LeonardWJWanCKIL-21 signaling in immunityF1000Res20165 pii: F1000 Faculty Rev-224
- Chávez-BlancoAChacón-SalinasRDominguez-GomezGViral inhibitors of NKG2D ligands for tumor surveillanceExpert Opin Ther Targets201620111375138727322108
- LanierLLNKG2D receptor and its ligands in host defenseCancer Immunol Res20153657558226041808
- CerqueiraBBLashamAShellingANAl-KassasRNanoparticle therapeutics: technologies and methods for overcoming cancerEur J Pharm Biopharm201597Pt A14015126515260
- ZhaoPLZhaoYJLengJGongWJStudy of NK cell activation by colon cancer cells genetically modified with NKG2D-IL-21 fusion gene ex vivoJ Clin Med in Practice201620114 Chinese
- HuHYuLTanSTuKWangLQNovel complex hydrogels based on N-carboxyethyl chitosan and quaternized chitosan and their controlled in vitro protein release propertyCarbohydr Res2010345446246820096400
- WuJWeiWWangLYSuZGMaGHA thermosensitive hydrogel based on quaternized chitosan and poly (ethylene glycol) for nasal drug delivery systemBiomaterials200728132220223217291582
- MaHLWhittersMJKonzRFIL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gammaJ Immunol2003171260861512847225
- WangGTschoiMSpolskiRIn vivo antitumor activity of interleukin 21 mediated by natural killer cellsCancer Res200363249016902214695220
- BradyJHayakawaYSmythMJNuttSLIL-21 induces the functional maturation of murine NK cellsJ Immunol200417242048205814764669
- NakanoHKishidaTAsadaHInterleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinomaJ Gene Med200681909916097036
- DavisMRZhuZHansenDMBaiQFangYThe role of IL-21 in immunity and cancerCancer Lett2015358210711425575696
- SøndergaardHSkakKIL-21: roles in immunopathology and cancer therapyTissue Antigens200974646747919845910
- SaadeFPetrovskyNTechnologies for enhanced efficacy of DNA vaccinesExpert Rev Vaccines201211218920922309668
- BertrandNWuJXuXKamalyNFarokhzadOCCancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biologyAdv Drug Deliv Rev201466122524270007
- LiuBSStoopJNHuizingaTWToesREIL-21 enhances the activity of the TLR-MyD88-STAT3 pathway but not the classical TLR-MyD88-NF-κB pathway in human B cells to boost antibody productionJ Immunol201319184086409424043893
- LiSNWangWFuSPIL-21 modulates release of proinflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathwaysMediators Inflamm2013201354807324574581
- SchmidtSRFusion-proteins as biopharmaceuticals-applications and challengesCurr Opin Drug Discov Devel2009122284289
- LichtorTGlickRPImmunogene therapyAdv Exp Med Biol201274615116522639166
- Huergo-ZapicoLAcebes-HuertaAGonzalez-RodriguezAPExpansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive diseasePLoS One2014910e10832625286418
- RoshaniRBoroujerdniaMGTalaiezadehAHKhodadadiAAssessment of changes in expression and presentation of NKG2D under influence of MICA serum factor in different stages of breast cancerTumour Biol20163756953696226662806
- ZhangTSentmanCLCancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cellsCancer Res20117162066207621282338